Kenvue Inc. (KVUE) Q3 2026 (USD): Adj. EPS 0.29 (exp. 0.29), Revenue 3.9bln (exp. 3.86bln)

• Net sales increased 3.2% vs the prior year period, reflecting Organic sales growth of 2.9% and a foreign currency benefit of 0.3%.
• Gross profit margin was 59.5% (prev. 59.1%)
• Adjusted gross profit margin was 61.5% (prev. 61.2% Y/Y)
• Operating income margin was 18.2% (prev. 16.7% Y/Y).
• Adjusted operating income margin was 21.9% (prev. 21.5% Y/Y)

An in-line EPS print on a modest revenue beat is the template for a muted single-stock reaction in consumer staples: the shares tend to trade on the organic growth line and the margin trajectory rather than the headline match, since the category is valued on volume recovery and pricing power rather than surprises. The details here, organic growth in the low single digits with a small currency contribution and gross and operating margins expanding year on year, follow the sector pattern where staples groups have leaned on cost discipline and pricing while volumes stay soft. Worth distinguishing between genuine volume-led growth and price/mix carrying the print, as the former has historically been the more durable re-rating trigger in this group. Kenvue's own context matters: since separating from its former parent, the stock has been judged on whether the consumer health portfolio can deliver mid-single-digit organic growth, and prints like this have tended to settle questions of execution rather than re-rate the equity. The follow-ons are the guidance language on the call, any commentary on category demand in self-care and skin health, and whether margin gains are reinvested in brand support, which has historically been the tell on management confidence in the top line.